Therapeutic pathways of allogeneic and autologous hematopoietic stem cell transplantation recipients: a hospital pharmacist’s perspective
DOI:
https://doi.org/10.30827/ars.v65i3.30246Keywords:
hematopoietic stem cell transplantation, C-reactive protein, Model for End-stage Liver Disease score, potentially inappropriate medications, anticholinergic burden score, Hepatic Insufficiency, list of potentially inappropriate medicationsAbstract
Introduction: Patients undergoing allogeneic and autologous hematopoietic stem cell transplantation (Allo-HSCT and Auto-HSCT) are at risk of pharmacotherapy-related problems.
Objective: To describe in Allo-HSCT and Auto-HSCT patients from admission to hospital discharge, their therapeutic profile, and the time-course of biomarkers of renal and liver dysfunction, and of inflammation to display a more specific overview of drug therapy in HSCT patients.
Method: Data were retrospectively extracted from the charts of 20 Allo-HSCT and 20 Auto-HSCT patients. The therapeutic pathway was described by the turn-over of drug treatments, the potentially inappropriate medications by using the GO-PIM scale, and the anticholinergic burden. Patho-physiological variations affecting clearance organs were characterized by the C-Reactive Protein (CRP) levels, and the hepatic and renal impairment evaluation tools (Model for End-stage Liver Disease score: MELD score, and glomerular filtration rate: GFR).
Results: Compared to Auto-HSCT patients, Allo-HSCT patients had a higher number of drugs initiated during hospital stay leading to hyper-polypharmacy during the stay and at discharge. Around 35 % of drugs used were metabolized by CYP3A4 in HSCT patients. Anticholinergic burden increased at discharge in HSCT patients. Auto-HSCT patients ≥ 65 years were taking at least one PIM. High CRP levels were reported in HSCT recipients. MELD score increased and GFR decreased in Allo-HSCT patients while GFR slightly increased in Auto-HSCT patients.
Conclusion: Clinical pharmacist should target polypharmacy, PIM and anticholinergic burden, and evaluate inflammation and both renal and hepatic functions in order to thoughtfully assess the clearance potential of patients and to suggest individualized dosing.
Downloads
References
Sanchez L, Bacle A, Lamy T, Le Corre P. Potential drug-drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay. Cancer Chemother Pharmacol. 2019;83(5):827-835. doi: 10.1007/s00280-019-03791-9. DOI: https://doi.org/10.1007/s00280-019-03791-9
Langebrake C, Admiraal R, van Maarseveen E, Bonnin A, Bauters T. EBMT Working Group. EBMT Working Group. Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55(1):62-69. doi: 10.1038/s41409-019-0538-9. DOI: https://doi.org/10.1038/s41409-019-0538-9
Clemmons AB, Alexander M, DeGregory K, Kennedy L. The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group. Biol Blood Marrow Transplant. 2018;24(5):914-922. doi: 10.1016/j.bbmt.2017.12.803. DOI: https://doi.org/10.1016/j.bbmt.2017.12.803
FACT-JACIE International Standards for Hematopoietic Cellular Therapy. In. 8 edn, version 8.1 december 14, 2021. https://www.factglobal.org/media/qpvn2kph/sts_5_2_041_fact-jacie-standards-eighth-edition_8_1_r2_12142021_forweb.pdf. Accessed April 3, 2023.
Visacri MB, Tavares MG, Barbosa CR, Duarte NC, Moriel P. Clinical pharmacy in onco-hematology and bone marrow transplant: A valuable contribution to improving patient safety. J Oncol Pharm Pract. 2021;27(5):1172-1180. doi: 10.1177/1078155220943964. DOI: https://doi.org/10.1177/1078155220943964
Duncan N, Moreno-Martinez ME, Pires V, Domingos V, Bonnin A, Nezvalova-Henriksen K, et al. Pharmacist Committee of the EBMT. Role and competencies of the EBMT clinical pharmacists and clinical pharmacologists: a pan-European survey. Bone Marrow Transplant. 2023 7. doi: 10.1038/s41409-023-01983-9. DOI: https://doi.org/10.1038/s41409-023-01983-9
Hshieh TT, DuMontier C, Jaung T, Bahl NE, Hawley CE, Mozessohn L, et al. Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers. J Natl Compr Canc Netw. 2022;20(8):915-923.e5. doi: 10.6004/jnccn.2022.7033. DOI: https://doi.org/10.6004/jnccn.2022.7033
Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, et al. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014;38(10):1184-90. doi: 10.1016/j.leukres.2014.06.018. DOI: https://doi.org/10.1016/j.leukres.2014.06.018
Dhakal P, Lyden E, Muir KE, Al-Kadhimi ZS, Koll T, Maness LJ, et al. Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia. Leuk Lymphoma. 2020;61(7):1702-1708. doi: 10.1080/10428194.2020.1737687. DOI: https://doi.org/10.1080/10428194.2020.1737687
Lin RJ, Ma H, Guo R, Troxel AB, Diefenbach CS. Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities. Br J Haematol. 2018;180(2):267-270. DOI: https://doi.org/10.1111/bjh.15027
Bhargava D, Arora M, DeFor TE, Brunstein CG, Thyagarajan B, El Jurdi N, et al. Use of Potentially Inappropriate Medications in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2020;26(12):2329-2334. DOI: https://doi.org/10.1016/j.bbmt.2020.08.031
Sugidono M, Lo M, Young R, Rosario K, Jung Y, Huang CY, et al. Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults. Transplant Cell Ther. 2021;27(4):344.e1-344.e5. DOI: https://doi.org/10.1016/j.jtct.2021.01.001
Hingorani S. Renal Complications of Hematopoietic-Cell Transplantation. N Engl J Med. 2016;374(23):2256-67. doi: 10.1056/NEJMra1404711. DOI: https://doi.org/10.1056/NEJMra1404711
Carreras E. Risk assessment in haematopoietic stem cell transplantation: the liver as a risk factor. Best Pract Res Clin Haematol. 2007;20(2):231-46. doi: 10.1016/j.beha.2006.10.010. DOI: https://doi.org/10.1016/j.beha.2006.10.010
Golla K, Mannell H, Benesic A, Dreischulte T, Grill E, Strobach D. Feasibility of the MELD score as a screening tool for pharmacists to identify patients with impaired hepatic function at hospital admission. J Clin Pharm Ther. 2022;47(5):676-684. doi: 10.1111/jcpt.13597. DOI: https://doi.org/10.1111/jcpt.13597
Lenoir C, Rollason V, Desmeules JA, Samer CF. Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature. Front Pharmacol. 2021 ;16;12:733935. doi: 10.3389/fphar.2021.733935. DOI: https://doi.org/10.3389/fphar.2021.733935
Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311-320. doi:10.2217/1745509X.4.3.311 DOI: https://doi.org/10.2217/1745509X.4.3.311
Briet J, Javelot H, Heitzmann E, Weiner L, Lameira C, D’Athis P, et al. The anticholinergic impregnation scale: Towards the elaboration of a scale adapted to prescriptions in French psychiatric settings. Therapie. 2017;72(4):427-437. doi: 10.1016/j.therap.2016.12.010. DOI: https://doi.org/10.1016/j.therap.2016.12.010
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. DOI: https://doi.org/10.1093/nar/gkx1037
Mekonnen A, Redley B, Crawford K, Jones S, de Courten B, Manias E. Prescribing with clinical and functional outcomes in older adults. Expert Opin Drug Saf. 2022;21(7):985-994. doi: 10.1080/14740338.2022.2044786. DOI: https://doi.org/10.1080/14740338.2022.2044786
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65. DOI: https://doi.org/10.1517/14740338.2013.827660
Pelletier K, Côté G, Madsen K, Chen S, Kim SJ, Chan CT, et al. Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant. Clin Kidney J. 2022; 15(8):1583-1592. doi: 10.1093/ckj/sfac091. DOI: https://doi.org/10.1093/ckj/sfac091
Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R; French Society of Pharmacology and Therapeutics. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215:107627. doi: 10.1016/j.pharmthera.2020.107627. DOI: https://doi.org/10.1016/j.pharmthera.2020.107627
Le Carpentier EC, Canet E, Masson D, Martin M, Deslandes G, Gaultier A, et al. Impact of Inflammation on Midazolam Metabolism in Severe COVID-19 Patients. Clin Pharmacol Ther. 2022;112(5):1033-1039. doi: 10.1002/cpt.2698. DOI: https://doi.org/10.1002/cpt.2698
Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, Florentin I, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther. 1994;55(6):649-60. doi: 10.1038/clpt.1994.82. DOI: https://doi.org/10.1038/clpt.1994.82
Amigues I, Cohen N, Chung D, Seo SK, Plescia C, Jakubowski A, et al. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(1):46-52. doi: 10.1016/j.bbmt.2009.08.015. DOI: https://doi.org/10.1016/j.bbmt.2009.08.015
Tverdek FP, Kofteridis D, Kontoyiannis DP. Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther. 2016;14(8):765-76. doi: 10.1080/14787210.2016.1199272. DOI: https://doi.org/10.1080/14787210.2016.1199272
Liang CK, Chou MY, Hsu YH, Wang YC, Liao MC, Chen MT, et al. The association of potentially inappropriate medications, polypharmacy and anticholinergic burden with readmission and emergency room revisit after discharge: A hospital-based retrospective cohort study. Br J Clin Pharmacol. 2023;89(1):187-200. doi: 10.1111/bcp.15457. DOI: https://doi.org/10.1111/bcp.15457
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-13. doi: 10.1001/archinternmed.2007.106. DOI: https://doi.org/10.1001/archinternmed.2007.106
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 David Malnoe, Timothé Lamande, Alexia Jouvance-Le Bail, Tony Marchand, pascal le corre
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
